Inogen Releases Innovative Inogen One G4™ Oxygen Concentrator
GOLETA, Calif.--(BUSINESS WIRE)-- Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the release to market of its innovative Inogen One G4 portable oxygen concentrator. The ultra-portable device is the smallest and lightest oxygen concentrator that the Company has ever produced, and the Company expects the product to be embraced by long-term oxygen therapy users worldwide.
At only 2.8 pounds, the Inogen One G4 is small and light-weight, allowing it to seamlessly fit into the lifestyles of active oxygen therapy patients. Compared to the popular Inogen One G3, the Inogen One G4 is more than 40% lighter and is approximately half the size. Weighing less than commonly used oxygen tanks, the Inogen One G4 can easily be carried over the shoulder, worn on the hip or belt, or carried in a convenient backpack with optional accessories. With three flow settings and Inogen’s standard Intelligent Delivery Technology, the Inogen One G4 was designed to meet the clinical needs of greater than 85% of patients that express an interest in the Company’s products as a single solution for oxygen therapy – at home, away, and for travel. Other patient-preferred features include a long battery life of up to 6 hours with the optional double battery, a large LCD screen, and very quiet operation.
The Inogen One G4 represents a step forward in innovation within the oxygen therapy market. The Company believes that the Inogen One G4 boasts the highest oxygen output per pound of weight of any oxygen concentrator currently available in the supplemental oxygen therapy US homecare market. It is Inogen’s mission to push the boundaries of conventional design and to develop innovative and patient-preferred oxygen technology so that patients can reclaim their freedom and independence.
“The Inogen One G4 exemplifies Inogen’s spirit of innovation and dedication to designing products specifically for the end consumer, the oxygen therapy user,” said Raymond Huggenberger, Inogen’s CEO. “We are extremely proud of the level of innovation that we are delivering to patients, and we look forward to hearing about the lives changed because of the Inogen One G4.”
The Inogen One G4 has been released for sale to oxygen therapy patients in the Company’s direct-to-consumer sales channel and is expected to be made available to additional sales channels, including domestic and international business-to-business channels (pending receipt of any required foreign regulatory approvals), through a controlled rollout process over the coming months.
In addition, on May 24th 2016 the Department of Transportation and the Federal Aviation Administration published a final rule concerning the acceptance criteria for portable oxygen concentrators used on board aircraft. The final rule replaces the current product by product approval process and allows commercial aircraft passengers to use a portable oxygen concentrator on board if the portable concentrator satisfies certain acceptance criteria and the product has a label indicating conformance with the acceptance criteria. The Inogen One G4 satisfies the necessary acceptance criteria; therefore the expected date that passengers will be able to travel on board commercial aircraft with the Inogen One G4 is the final rule implementation date, which is August 22nd, 2016. In the meantime, Inogen One G4 users are encouraged to contact the Company if they wish to travel via commercial aircraft to discuss options for traveling with the Inogen One G3 that is currently approved by the FAA.
Additional specifications for the Inogen One G4 can be found below:
|Weight||2.8 lbs. (includes single battery)|
|Height: 7.2" (includes single battery)|
|Oxygen Flow||Pulse dose delivery system|
|Three flow settings 1, 2, 3|
|Power||AC Power Supply 100-240V, 50-60Hz|
|(auto sensing to allow worldwide use)|
|DC Power Cable: for mobile use in car|
|Battery||Duration (single battery): Up to 3 hours|
|Recharge up to 3.25 hours with AC or DC power|
|Duration (double battery): Up to 6 hours|
|Recharge up to 6 hours with AC or DC power|
|Noise Level||40 dBA*|
|Operation||Simple control functions and easy-to-read LCD display|
|Use||Designed for 24/7 use|
*At flow setting 2
Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit http://investor.inogen.com/.
Use of Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning Inogen’s expectations for market acceptance of its Inogen One G4, the ability of the Inogen One G4 to meet the clinical needs of patients, expected product improvements to the Inogen One G4, Inogen’s belief that the Inogen One G4 can change and improve the lives of patients, the expected timing and distribution channels for the rollout of the Inogen One G4, and Inogen’s expectation that the Inogen One G4 will be allowed for use on commercial aircraft within the indicated timeframe. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks relating to market acceptance of Inogen’s products; competition; its sales, marketing and distribution capabilities; its planned sales, marketing, and research and development activities; interruptions or delays in the supply of components or materials for, or manufacturing of, its products; seasonal variations in customer operations; unanticipated increases in costs or expenses; risks associated with international operations, including risks associated with obtaining regulatory approval in foreign jurisdictions; and intellectual property risks if Inogen is unable to secure and maintain patent or other intellectual property protection for the intellectual property used in its products. Information on these and additional risks, uncertainties, and other information affecting Inogen's business and operating results are contained in Inogen's Annual Report on Form 10-K for the year ended December 31, 2015 and in Inogen's subsequent reports filed with the Securities and Exchange Commission, including Inogen's Quarterly Report on Form 10-Q for the period ended March 31, 2016. These forward-looking statements speak only as of the date hereof. Inogen disclaims any obligation to update these forward-looking statements except as may be required by law.
Inogen is innovation in oxygen therapy. We are a medical technology
company that develops, manufactures and markets innovative oxygen
concentrators used to deliver supplemental long-term oxygen therapy to
patients suffering from chronic respiratory conditions.
For more information, please visit www.inogen.com.
Investor Relations Contact:
805-562-0500 ext. 7
Byron Myers, 805-562-0503
Source: Inogen, Inc.
Released May 31, 2016